METASTASIS

ABSTRACT

The limited effectiveness of approved treatments, as well as evidence of their resistance and toxicities, emphasize the need for the development of new therapeutic monoclonal antibodies to improve the efficacy of metastases in tumors in the breast or pancreas, or in hematological tumors (leukemias And lymphomas).

The METASTASIS project works on the following clearly defined and differentiated objectives:

• • FIBHULP has found in in vitro experiments that the monoclonal antibody against CCR7 is effective in a large number of leukemias and lymphomas.
  • IMMED has begun the development of animal models of those diseases in which FIBHULP has demonstrated efficacy of the monoclonal antibody against CCR7.
  • LEITAT has performed the selection of tumor lines to perform efficacy studies with the monoclonal antibodies against S100A4, S100P and S100A7 as well as the production of the necessary amount of antibody against the three proteins prior to the in vitro functional studies (on the fly) and in vivo.

The consortium is carrying out a company, Immunological and Medicinal Products (IMMED) and two centers of recognized international prestige: the Foundation for Biomedical Research of the Hospital Universitario de la Princesa (FIBHULP) and the Leitat technology center. IMMED is a company with extensive experience in the development of molecular diagnostic methods and therapies for oncology and inflammatory and autoimmune diseases. IMMED will participate in pre-clinical and functional validation of antibody leads. The FIBHULP center will participate in the in vitro assays of antibody binding and Leitat will participate in determining the efficacy of antibody activity in cell lines and the determination of antiangiogenic and antimetastase activity in animal models in vivo. This strategy is expected to improve the efficacy of metastatic treatments for tumors in the breast or pancreas.